Developer docs
API playgroundTry for free, no card

Search company profiles

Spannerwerks

Full company profile

uuid000k6h1

Namestring
Spannerwerks
Legal namestring
Spannerwerks, LLC
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Spannerwerks is a Seattle-based drug development consulting firm that deploys a consortium of senior subject-matter experts and project managers to pharmaceutical and biotechnology companies at critical inflection points in the drug development lifecycle — including IND and BLA filings, clinical study start-ups, CMC program management, and commercial launch readiness. The firm sells time and expertise rather than a software platform; its delivery model is to embed consultants inside client organizations, integrating with internal teams and flexing up or down as project needs dictate. Revenue is generated through professional-services engagements, with pricing tied to project scope and duration rather than a standardized fee schedule.

The firm was founded in 2015 and rebranded in 2020 around the tagline 'Experience | Expertise | Execution,' coinciding with its public repositioning and initial case-study marketing. The leadership team comprises four named principals — CEO Dara Lockert, Chief Business Officer Brian Miller, Director of Product Development Consulting Lori Hansen (PhD), and Director of CMC Technical Consulting Patsy Lewis — each with 25+ years of biopharma experience spanning biologics, gene therapy, immunotherapy, genomics, and vaccines. Documented engagements include IND completion in nine months for a university-backed immune-oncology startup, CMC and quality program management enabling on-schedule BLA filing during COVID-19, and commercial-launch team streamlining for a mid-market biopharma that was subsequently acquired.

On October 23, 2025, Spannerwerks was acquired by Alloy Therapeutics and operates as a wholly-owned subsidiary within Alloy's broader R&D services platform. Pre-acquisition, the firm operated as a private LLC with 1–10 employees, direct B2B sales motion, no disclosed funding, no patents or proprietary technology assets, and no AI/ML component to its offering.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug development consulting, biotech consulting services, pharmaceutical project management, CMC technical consulting, IND filing support
Industry3 codes
PRIMARYHLAGACAE
Clinical Trial Site Operations & Study Coordination
SECONDARYHLAGACAG
Clinical Trial Monitoring Support (On-site/Remote)
SECONDARYHLAGACAB
Site Identification & Feasibility
NAICS code2 codes
  • Other Scientific and Technical Consulting Services541690
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code2 codes
  • Services-Management Consulting Services8742
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical Drug Development Consulting
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development Consulting Services
TypeProfessional Services
Description

Professional services revenue generated through consulting engagements with pharmaceutical and biotech companies. Services include project management, subject matter expertise, and integrated program management throughout the drug development lifecycle from preclinical to commercial launch.

spannerwerks.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Spannerwerks provides a consortium of experienced project management professionals and subject matter experts to pharmaceutical and biotech companies throughout the drug and biologic development lifecycle. Services span IND filing support, clinical trial initiation and management, CMC technical consulting, regulatory submission support, and commercial launch readiness, with experts embedded in client teams during critical inflection points.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • FDA filing completed in 9 months including GMP tech transfer and final clinical protocol
+2 more records
Product overview1 text field

Spannerwerks is a drug development consulting firm offering a consortium of experienced project management professionals and subject matter experts. The company provides flexible consulting services across all phases of drug and biologic development and commercialization, including IND filing support, clinical trial management, CMC technical consulting, program management, and commercial launch readiness. Their model allows clients to engage experts as needed to fill organizational gaps during critical inflection points such as filing INDs, starting studies, or commercializing new products.

Product and service1 record
1Drug Development Consulting Services
CategoryDrug Development Consulting
Description

A consortium of experienced project management professionals and subject matter experts providing support throughout the drug development process, including IND filing, clinical trial management, CMC consulting, and commercial launch readiness for pharmaceutical and biotech companies.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-10-23
Description

Alloy Therapeutics acquired Spannerwerks to expand its capabilities in drug development and support partners through the entire R&D lifecycle. The acquisition brings Spannerwerks' consulting expertise in drug development under Alloy's broader platform, enhancing end-to-end R&D services for biotechnology and pharmaceutical partners.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-04-28
Description

Spannerwerks collaborated with BioEclipse Therapeutics to prepare for Phase 1 clinical trial for CRX100, a cancer immunotherapy candidate. Spannerwerks worked with BioEclipse to complete the IND filing for CRX100, providing executive director oversight and program management expertise. The collaboration successfully advanced this innovative immunotherapy from the laboratory into clinical trials.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Boston-based drug development consulting firm providing program leadership, regulatory, and CMC advisory to biotech and pharma. Closely comparable to Spannerwerks in service mix, target customer (early- to mid-stage biotech), and senior-consultant-led delivery model.

TypeDirect peer
Description

Specialist cell and gene therapy consulting firm supporting CMC, manufacturing, and regulatory strategy. Highly comparable in modality focus and boutique senior-expert positioning, with overlap on gene therapy and immunotherapy clients served by Spannerwerks.

TypeDirect peer
Description

Pharmaceutical consulting and compliance services firm covering regulatory affairs, clinical research, and quality/compliance. Comparable to Spannerwerks in serving pharma/biotech at development and commercialization inflection points with project-based engagements.

TypeDirect peer
Description

Regulatory and drug development consultancy serving pharma and biotech with submission strategy, dossier preparation, and product development advisory. Direct overlap with Spannerwerks' regulatory and CMC work and small/mid-cap biotech client base.

5Camargo Pharmaceutical Services
TypeDirect peer
Description

Drug development consultancy specializing in 505(b)(2), ANDA, and biologics development strategy and submissions. Comparable to Spannerwerks in the sponsor-side program management niche and serving similar biotech and mid-market pharma customers.

TypeDirect peer
Description

Pharmaceutical consulting firm focused on CMC, regulatory compliance, and technical operations for drug development and commercial manufacturing. Directly comparable to Spannerwerks' CMC consulting line of service and enterprise pharma engagement profile.

TypeBroad incumbent
Description

Global management consultancy with a life sciences practice offering commercial, clinical, and regulatory strategy to large pharma and biotech. Wider portfolio and larger bench than Spannerwerks, but competes for the same strategy and program leadership mandates.

8ZS Associates
TypeOthers
Description

Global management consulting firm serving pharma and biotech on commercial strategy, launch, and R&D operations. Overlaps with Spannerwerks on commercial launch readiness engagements for biopharma clients, but at much greater scale and broader service scope.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Spannerwerks

Pharmaceutical Drug Development Consultingspannerwerks.com

What Spannerwerks does

Spannerwerks is a Seattle-based drug development consulting firm that deploys a consortium of senior subject-matter experts and project managers to pharmaceutical and biotechnology companies at critical inflection points in the drug development lifecycle — including IND and BLA filings, clinical study start-ups, CMC program management, and commercial launch readiness. The firm sells time and expertise rather than a software platform; its delivery model is to embed consultants inside client organizations, integrating with internal teams and flexing up or down as project needs dictate. Revenue is generated through professional-services engagements, with pricing tied to project scope and duration rather than a standardized fee schedule.

The firm was founded in 2015 and rebranded in 2020 around the tagline 'Experience | Expertise | Execution,' coinciding with its public repositioning and initial case-study marketing. The leadership team comprises four named principals — CEO Dara Lockert, Chief Business Officer Brian Miller, Director of Product Development Consulting Lori Hansen (PhD), and Director of CMC Technical Consulting Patsy Lewis — each with 25+ years of biopharma experience spanning biologics, gene therapy, immunotherapy, genomics, and vaccines. Documented engagements include IND completion in nine months for a university-backed immune-oncology startup, CMC and quality program management enabling on-schedule BLA filing during COVID-19, and commercial-launch team streamlining for a mid-market biopharma that was subsequently acquired.

On October 23, 2025, Spannerwerks was acquired by Alloy Therapeutics and operates as a wholly-owned subsidiary within Alloy's broader R&D services platform. Pre-acquisition, the firm operated as a private LLC with 1–10 employees, direct B2B sales motion, no disclosed funding, no patents or proprietary technology assets, and no AI/ML component to its offering.

Spannerwerks firmographics

Firmographics
Name
Spannerwerks
Legal name
Spannerwerks, LLC
Website
https://spannerwerks.com
Company type
Private
Founded year
2020
Operating status
Acquired
Headcount range
1–10 employees
Ownership category
akta.pro rank

Spannerwerks industry classification

Industry
Product category
Pharmaceutical Drug Development Consulting
NAICS
Other Scientific and Technical Consulting Services (541690), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Management Consulting Services (8742), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGACAE
Clinical Trial Site Operations & Study Coordination
SECONDARYHLAGACAG
Clinical Trial Monitoring Support (On-site/Remote)
SECONDARYHLAGACAB
Site Identification & Feasibility

Keywords

  • Drug development consulting
  • Biotech consulting services
  • Pharmaceutical project management
  • CMC technical consulting
  • IND filing support

Where Spannerwerks is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Spannerwerks business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales

Revenue model

  1. Drug Development Consulting Services: Professional services revenue generated through consulting engagements with pharmaceutical and biotech companies. Services include project management, subject matter expertise, and integrated program management throughout the drug development lifecycle from preclinical to commercial launch.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Spannerwerks product offering

Product offering

Core offering

Spannerwerks provides a consortium of experienced project management professionals and subject matter experts to pharmaceutical and biotech companies throughout the drug and biologic development lifecycle. Services span IND filing support, clinical trial initiation and management, CMC technical consulting, regulatory submission support, and commercial launch readiness, with experts embedded in client teams during critical inflection points.

Product overview

Spannerwerks is a drug development consulting firm offering a consortium of experienced project management professionals and subject matter experts. The company provides flexible consulting services across all phases of drug and biologic development and commercialization, including IND filing support, clinical trial management, CMC technical consulting, program management, and commercial launch readiness. Their model allows clients to engage experts as needed to fill organizational gaps during critical inflection points such as filing INDs, starting studies, or commercializing new products.

Differentiator

Problem solved

Functional benefit

Products and services

  • Drug Development Consulting Services A consortium of experienced project management professionals and subject matter experts providing support throughout the drug development process, including IND filing, clinical trial management, CMC consulting, and commercial launch readiness for pharmaceutical and biotech companies.

Quantifiable outcome

  • FDA filing completed in 9 months including GMP tech transfer and final clinical protocol
  • +2 more outcomes

Companies that use Spannerwerks

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles1 record

Spannerwerks technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Spannerwerks partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship and core.

  • Alloy TherapeuticsflagshipStrategic or Co-development Partner · 23 October 2025Alloy Therapeutics acquired Spannerwerks to expand its capabilities in drug development and support partners through the entire R&D lifecycle. The acquisition brings Spannerwerks' consulting expertise in drug development under Alloy's broader platform, enhancing end-to-end R&D services for biotechnology and pharmaceutical partners.
  • BioEclipse TherapeuticscoreStrategic or Co-development Partner · 28 April 2020Spannerwerks collaborated with BioEclipse Therapeutics to prepare for Phase 1 clinical trial for CRX100, a cancer immunotherapy candidate. Spannerwerks worked with BioEclipse to complete the IND filing for CRX100, providing executive director oversight and program management expertise. The collaboration successfully advanced this innovative immunotherapy from the laboratory into clinical trials.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Spannerwerks competitors and assessment

Company assessment

Direct peers

  • Halloran Consulting Group: Boston-based drug development consulting firm providing program leadership, regulatory, and CMC advisory to biotech and pharma. Closely comparable to Spannerwerks in service mix, target customer (early- to mid-stage biotech), and senior-consultant-led delivery model.
  • Dark Horse Consulting: Specialist cell and gene therapy consulting firm supporting CMC, manufacturing, and regulatory strategy. Highly comparable in modality focus and boutique senior-expert positioning, with overlap on gene therapy and immunotherapy clients served by Spannerwerks.
  • ProPharma Group: Pharmaceutical consulting and compliance services firm covering regulatory affairs, clinical research, and quality/compliance. Comparable to Spannerwerks in serving pharma/biotech at development and commercialization inflection points with project-based engagements.
  • NDA Group: Regulatory and drug development consultancy serving pharma and biotech with submission strategy, dossier preparation, and product development advisory. Direct overlap with Spannerwerks' regulatory and CMC work and small/mid-cap biotech client base.
  • Camargo Pharmaceutical Services: Drug development consultancy specializing in 505(b)(2), ANDA, and biologics development strategy and submissions. Comparable to Spannerwerks in the sponsor-side program management niche and serving similar biotech and mid-market pharma customers.
  • Lachman Consultants: Pharmaceutical consulting firm focused on CMC, regulatory compliance, and technical operations for drug development and commercial manufacturing. Directly comparable to Spannerwerks' CMC consulting line of service and enterprise pharma engagement profile.

Broad incumbents

  • Charles River Associates: Global management consultancy with a life sciences practice offering commercial, clinical, and regulatory strategy to large pharma and biotech. Wider portfolio and larger bench than Spannerwerks, but competes for the same strategy and program leadership mandates.

Others

  • ZS Associates: Global management consulting firm serving pharma and biotech on commercial strategy, launch, and R&D operations. Overlaps with Spannerwerks on commercial launch readiness engagements for biopharma clients, but at much greater scale and broader service scope.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Spannerwerks social profiles

Digital presence

Spannerwerks financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Spannerwerks leadership team

Management profile

Number of profiles

Profiles4 records

Spannerwerks funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Spannerwerks M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spannerwerks

What does Spannerwerks do?

Spannerwerks provides a consortium of experienced project management professionals and subject matter experts to pharmaceutical and biotech companies throughout the drug and biologic development lifecycle. Services span IND filing support, clinical trial initiation and management, CMC technical consulting, regulatory submission support, and commercial launch readiness, with experts embedded in client teams during critical inflection points.

Is Spannerwerks a public or private company?

Spannerwerks is a private company. It is classified as corporate owned and is currently acquired.

When was Spannerwerks founded?

Spannerwerks was founded in 2020. It employs 1 to 10 people.

Where is Spannerwerks based?

Spannerwerks is headquartered in Seattle, United States, in the North America region.

How does Spannerwerks make money?

One revenue line is on record: drug Development Consulting Services.

Who are Spannerwerks's main competitors?

Direct peers on record are Halloran Consulting Group, Dark Horse Consulting, ProPharma Group, NDA Group, Camargo Pharmaceutical Services and Lachman Consultants. Charles River Associates is listed as a broad incumbent. ZS Associates is listed as an others.

Does Spannerwerks have an API?

No public API is recorded for Spannerwerks.

What industry is Spannerwerks in?

Spannerwerks's product category is Pharmaceutical Drug Development Consulting. Its primary akta.pro industry code is HLAGACAE, Clinical Trial Site Operations & Study Coordination, with a secondary code of HLAGACAG, Clinical Trial Monitoring Support (On-site/Remote). Its NAICS code is 541690 and its SIC code is 8742.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals